Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
The acquisition was announced on October 18, 2026.
Silence Therapeutics plc, a Nasdaq-listed biotechnology company, has entered into an agreement to be acquired by Merck KGaA, Darmstadt, Germany. The acquisition was announced on October 18, 2026.
The transaction was disclosed via an 8-K filing. The acquisition will see Silence Therapeutics plc become a wholly-owned subsidiary of Merck KGaA.
As of the latest available data, Silence Therapeutics plc has a free float of 23,649,945 shares and 141,703,840 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.